Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies

$2,356,009ZIAFY2018CANIH

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Paper 36911670 Paper 36753564 Paper 36208017 Paper 35675429 Paper 35312769 Paper 32630017 Paper 32611684 Paper 32194667 Paper 32123080 Paper 31871266 Paper 31520528 Paper 31345777 Paper 31142380 Paper 30782819 Paper 30760587 Paper 30625226 Paper 30621280 Paper 30441807 Paper 30312900 Paper 30272049 Paper 30218597 Paper 30213644 Paper 29883379 Paper 29870741 Paper 29695631 Paper 29581296 Paper 29432154 Paper 29431691 Paper 29311317 Paper 29152082 Paper 29149102 Paper 28674083 Paper 28423727 Paper 28087047 Paper 27796910 Paper 27601652 Paper 27507537 Paper 27463727 Paper 27419635 Paper 27196771 Paper 27167198 Paper 27114443 Paper 27112173 Paper 26939705 Paper 26894650 Paper 26864110 Paper 26728879 Paper 26719540 Paper 26477977 Paper 26463707 Paper 26443804 Paper 26307499 Paper 26261303 Paper 26111884 Paper 26056938 Paper 25997032 Paper 25962108 Paper 25803818 Paper 25756664 Paper 25728039 Paper 25713356 Paper 25673808 Paper 25587125 Paper 25560410 Paper 25239937 Paper 25127689 Paper 24932299 Paper 24928849 Paper 24890727 Paper 24843166 Paper 24586548 Paper 24523358 Paper 24504816 Paper 24415939 Paper 24322577 Paper 24284520 Paper 24154691 Paper 24145282 Paper 24130723 Paper 24070652 Paper 23942212 Patent 9598492 Patent 9492564 Patent 9279019 Patent 9115196 Patent 8907060 Patent 8871906 Patent 8809502 Patent 8591889 Patent 8445216 Patent 8357783 Patent 8039593 Patent 7999077 Patent 7982011 Patent 7777019 Patent 7521054 Patent 7470775 Patent 7355012 Patent 7129332 Patent 7081518

Abstract

Because we observed that some patients treated with immunotoxins developed anti-tumor immunity, we have developed a syngeneic mouse tumor model to study interactions of the immune system with immunotoxin therapy. We have developed syngeneic mouse models to evaluate the combination of LMB-100 and check point inhibitors. We find that the direct injection of LMB-100 into tumors synergizes with anti-CTLA-4 given I.P. to produce complete tumor regressions and the development of anti-tumor immunity. These studies were done in a mouse breast cancer model and are being extended to other cancer types to determine how general the effect is. We are also evaluating other check point inhibitors. Based on these studies a clinical trial combining LMB-100 with a check point inhibitor is being planned to open at NCI this year in mesothelioma and lung cancer. To develop a new treatment for myeloma we have made new immunotoxins targeting BCMA that is expressed on almost all myelomas. To evaluate these immunotoxins in a relevant animal model, we produced myeloma cells expressing luciferase and grow them in mouse bone marrow. We find the anti-BCMA immunotoxins are very active in this model and are looking for a company to help develop these agents for clinical trials.

View original record on NIH RePORTER →